INS and gestational diabetes: Until recently it was believed that transfer across the placenta was minimal; however, evidence from its use in gestational diabetes mellitus (GDM) now clearly shows that glibenclamide crosses the placenta 6, 7 and stimulates fetal insulin secretion, resulting in increased fetal growth and increased rates of neonatal hypoglycaemia 8, 9, 10.